Verve Gene Therapy Cuts Cholesterol 62% in 35-Patient Trial as Lilly Bets $1 Billion
Updated
Updated · The Philadelphia Inquirer · May 28
Verve Gene Therapy Cuts Cholesterol 62% in 35-Patient Trial as Lilly Bets $1 Billion
12 articles · Updated · The Philadelphia Inquirer · May 28
VERVE-102 cut LDL cholesterol by 62% within a month at the highest dose in an early trial of 35 high-risk patients, with the results published in the New England Journal of Medicine.
The one-time therapy edits the liver gene PCSK9 to mimic naturally protective mutations that switch it off, aiming to replace daily cholesterol drugs that many patients fail to keep taking.
Up to 90 days of follow-up at the strongest-response doses suggested the effect may last, and no major treatment-related adverse events were reported in the latest study.
Safety remains the key hurdle after Verve's earlier candidate was paused over elevated liver enzymes; gene-editing trials typically require 15 years of follow-up and larger studies.
Eli Lilly acquired Verve for $1 billion last year, underscoring the commercial stakes if a durable, one-and-done cholesterol treatment can eventually be made broadly accessible.
Is this 'one-and-done' cholesterol cure worth the risk of a permanent, irreversible genetic mistake?
With new tech boosting gene-editing to 90% efficiency, is VERVE-102 already becoming outdated before its next trial?
VERVE-102 Phase 1b Results: 62% LDL-C Drop with One-Time Gene Editing—Eli Lilly’s Bold Bet on the Future of Cardiovascular Medicine
Overview
Eli Lilly’s acquisition of Verve Therapeutics led to the development of VERVE-102, an innovative gene therapy designed to permanently lower LDL cholesterol. In the Phase 1b Heart-2 trial, 35 adults with high cardiovascular risk received a single infusion of VERVE-102. The results showed significant and lasting reductions in both LDL cholesterol and PCSK9 protein levels, demonstrating the therapy’s strong potential. This breakthrough highlights a shift from ongoing treatments to a one-time genetic solution, offering new hope for patients with difficult-to-control cholesterol and marking a major advance in cardiovascular care.